Continuous subcutaneous insulin infusion (CSII) is an intensive therapy typically reserved for motivated patients with type 1 diabetes (T1D) who have frequent hypoglycemia, a significant dawn phenomenon (excess hepatic glucose production and non-hepatic insulin resistance in the morning period) or widely fluctuating blood glucose when using multiple daily injections (MDIs) [1•]. This evidence concerns the gene INS and Hypoglycemia.